Crystalline form of benzylbenzene sglt2 inhibitor
AssigneeTheracos, Inc.
InventorsMengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Y. Roberge
Life of this patent
Estimating the term…
Abstract
Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
Claims45
A crystalline form of the compound of the formula:
A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a crystalline form of the compound (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
Dependencies are inferred from the claim text.